

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/HC25560B4CADEN.html>

Date: August 2022

Pages: 161

Price: US\$ 3,500.00 (Single User License)

ID: HC25560B4CADEN

Abstracts

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Histone Deacetylase 1 - Drugs In Development, 2022'; Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 38 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes.

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.

The report 'Histone Deacetylase 1 - Drugs In Development, 2022' outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development,

mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 7, 1, 1, 15 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Diffuse Large B-Cell Lymphoma, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Mycosis Fungoides, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2^{li}Breast Cancer), Liver Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Unspecified B-Cell Lymphomas, Adenoid Cystic Carcinoma (ACC), Alzheimer's Disease, Anal Cancer, Anaplastic Astrocytoma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Beta Thalassaemia, Bladder Cancer, Blood Cancer, Bone Disorders, Cervical Cancer, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Cognitive Disorders, Colon Cancer, Duchenne Muscular Dystrophy, Gallbladder Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hemoglobinopathies, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neuroendocrine Carcinoma, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer,

Parkinson's Disease, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Sezary Syndrome, Sickle Cell Disease, Skin Cancer, Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), T-Cell Lymphomas, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified Cancer, Unspecified Central Nervous System Disorders, Ureter Cancer, Urethral Cancer and Vulvar Cancer.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development

4D Pharma Plc

4SC AG

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Co

Curis Inc

GNT Biotech and Medicals Corp

Italfarmaco SpA

Jubilant Therapeutics Inc

Medibiofarma SL

Medivir AB

MEI Pharma Inc

Merck & Co Inc

Mirati Therapeutics Inc

Neuroene Therapeutics LLC

Oceanyx Pharmaceuticals Inc

OnKure Inc

Regenacy Pharmaceuticals LLC

Shenzhen Chipscreen Biosciences Co Ltd

Shuttle Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles

ACY-1035 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ACY-1071 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ACY-738 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ACY-957 - Drug Profile

Product Description

Mechanism Of Action

History of Events

crocetin - Drug Profile

Product Description

Mechanism Of Action

entinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

fimepinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

givinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

GNTbm-04 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GNTbm-38 - Drug Profile

Product Description

Mechanism Of Action

History of Events

JBI-128 - Drug Profile

Product Description

Mechanism Of Action

History of Events

largazole - Drug Profile

Product Description

Mechanism Of Action

History of Events

MBF-015 - Drug Profile

Product Description

Mechanism Of Action

MitoDak - Drug Profile

Product Description

Mechanism Of Action

mocetinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

MRx-0029 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MRX-1299 - Drug Profile

Product Description

Mechanism Of Action

History of Events

OKI-179 - Drug Profile

Product Description

Mechanism Of Action

History of Events

pracinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

purinostat mesylate - Drug Profile

Product Description

Mechanism Of Action

History of Events

RCY-1305 - Drug Profile

Product Description
Mechanism Of Action
History of Events
RCY-1410 - Drug Profile
Product Description
Mechanism Of Action
remetinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
resminostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
RG-2833 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit HDAC1 and HDAC6 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit HDAC1, HDAC2 and HDAC3 for Burkitt Lymphoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit HDAC1 and 2 for Cognitive Dysfunction - Drug Profile
Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit HDAC1 and HDAC2 for Hemoglobinopathies - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

SP-1161 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SP-1303 - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

History of Events

tucidinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

vorinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones

Featured News & Press Releases

Jun 25, 2022: Italfarmaco Group announces positive topline data from phase 3 trial showing beneficial effect of givinostat in patients with Duchenne Muscular Dystrophy

Jun 02, 2022: OnKure Therapeutics announces first patient dosed in the phase 1b/2 Nautilus trial of OKI-179 in combination with binimetinib in patients with advanced NRAS-mutated melanoma

May 05, 2022: 4SC - Resminostat and RESMAIN study update

Apr 08, 2022: OnKure Therapeutics announces promising preclinical data on OKI-179 in RAS-mutated tumor models presented in a late-breaking session at AACR

Mar 08, 2022: OnKure Therapeutics to present late-breaking preclinical data on OKI-179 at the AACR Annual Meeting 2022

Feb 22, 2022: 4D pharma announces FDA clearance of IND application for Live Biotherapeutic MRx0029 for the treatment of Parkinson's disease

Dec 14, 2021: OnKure Therapeutics announces positive topline first-in-human phase 1 results for OKI-179

Dec 01, 2021: Licensing partner of Shenzhen Chipscreen Biosciences - HUYABIO International, receives regulatory approval for Chidamide monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

Nov 30, 2021: HUYABIO International receives regulatory approval for Hiyasta monotherapy of peripheral t-cell lymphoma In Japan

Nov 25, 2021: Approval for additional indication of Hiyasta tablets for relapsed or refractory PTCL treatment in Japan

Nov 18, 2021: Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Oct 19, 2021: HUYABIO International launches Hiyasta as monotherapy for adult T-cell leukemia/lymphoma in Japan

Oct 07, 2021: Kyowa Kirin announces discontinuation for developing KHK237 (Entinostat)

Sep 21, 2021: HUYABIO announces first patient treated in a pivotal study of HBI-8000 combined with Opdivo (nivolumab) in patients with advanced melanoma

Aug 16, 2021: University of North Carolina Lineberger Comprehensive Cancer Center: Experimental drug that boosts immunotherapy shows promise in bladder cancer study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by 4D Pharma Plc, 2022

Pipeline by 4SC AG, 2022

Pipeline by BioMarin Pharmaceutical Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Curis Inc, 2022

Pipeline by GNT Biotech and Medicals Corp, 2022

Pipeline by Italfarmaco SpA, 2022

Pipeline by Jubilant Therapeutics Inc, 2022

Pipeline by Medibiofarma SL, 2022

Pipeline by Medivir AB, 2022

Pipeline by MEI Pharma Inc, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Mirati Therapeutics Inc, 2022

Pipeline by Neuroene Therapeutics LLC, 2022

Pipeline by Oceanyx Pharmaceuticals Inc, 2022

Pipeline by OnKure Inc, 2022

Pipeline by Regenacy Pharmaceuticals LLC, 2022

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Pipeline by Shuttle Pharmaceuticals Inc, 2022

Pipeline by Syndax Pharmaceuticals Inc, 2022

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/HC25560B4CADEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HC25560B4CADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

